Purchase this article with an account.
ER Craven, N Choplin, C Larsen, M Olson, S Whitcup; A 3-month Comparison of Efficacy and Safety of Brimonidine-tartrate 0.2% / Timolol 0.5% Fixed Combination (bid) With Timolol 0.5% (bid) or Brimonidine-tartrate 0.2% (tid) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):282.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the IOP-lowering efficacy of fixed combination brimonidine 0.2%/timolol 0.5% BID (BrimTim) with timolol 0.5% BID or brimonidine 0.2% (ALPHAGAN®) TID. Methods: Data were pooled from 2 identical, randomized, double-masked, multi-center trials. Adult patients with glaucoma or OHT (IOP 22-34 mmHg) received 1 of the above 3 treatment regimens. IOP was measured at day 0, week 2, week 6, and month 3 at 8am, 10am, 3pm, and 5pm. Results: View OriginalDownload SlideView OriginalDownload Slide Mean baseline IOP was similar among the three groups. In subsequent visits, mean IOP was lower with BrimTim than with either brimonidine or timolol at all time points; these differences were statistically significant at 11 out of 12 time points (p< 0.018). Reduction in mean IOP from baseline at 10am (peak effect), month 3 was 7.6 mm Hg with BrimTim, compared to 5.5 mm Hg with brimonidine (p<0.001) and 5.6 mm Hg with timolol (p<0.001). BrimTim also achieved IOP below specified target pressures (<18 mm Hg, or ≷20% decrease from baseline) over 3 months in more patients than either timolol or brimonidine alone (p≤0.010). Most of the treatment-related adverse events in all three groups were ocular and mild. BrimTim was well tolerated with few systemic side effects. Conclusion: The brimonidine/timolol fixed combination was safe and provided IOP reduction superior to that provided by either timolol or brimonidine monotherapy. Study supported by Allergan, Inc.
This PDF is available to Subscribers Only